Wong Li Ping, Lai Lee Lee, See Mee Hoong, Alias Haridah, Syed Omar Sharifah Faridah, Ng Chong Guan, Ho Gwo Fuang, Ong Teng Aik, Wong Yee Chi, Ooi Po Lin, Elias Jasmin Munchar, Hu Zhijian, Lin Yulan
Centre for Epidemiology and Evidence-Based Practice, Department of Social and Preventive Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China.
Front Psychol. 2022 Jul 26;13:906067. doi: 10.3389/fpsyg.2022.906067. eCollection 2022.
This study aims to describe the adverse events following immunization (AEFIs) of SARS-CoV-2 vaccination in cancer patients/survivors associated with their psychological distress.
A cross-sectional study was conducted to assess AEFIs after the receipt of SARS-CoV-2 vaccines in cancer patients/survivors attending a university hospital in Malaysia. Psychological distress was measured using the Hospital Anxiety and Depression Scale (HADS) before and after the first and second doses of COVID-19 vaccine.
A total of 217 complete responses were received. Compared with before vaccination, both HADS Anxiety (HADS-A) and HADS Depression (HADS-D) scores were significantly reduced after the first and second dose of the SARS-CoV-2 vaccine. Most of the participants had mild-or-moderate systemic and local AEFIs, with the most common being pain at the injection site, tiredness, and headache for both the first and second doses of the vaccine. Positive correlations between the total AEFI score and HADS-A ( = 0.309, < 0.001) and HADS-D ( = 0.214, = 0.001) scores were observed after the first dose of the SARS-CoV-2 vaccine. Similarly, positive associations were observed between the total AEFI score and HADS-A ( = 0.305, < 0.001) and HADS-D ( = 0.235, < 0.001) scores after the second dose of the SARS-CoV-2 vaccine.
Mild-to-moderate AEFIs found in this study help address vaccine hesitancy in cancer patients/survivors. Receiving the SARS-CoV-2 vaccine had a positive effect on decreasing psychological distress in cancer patients/survivors. High severity of an AEFI was associated with higher anxiety and depressive symptoms.
本研究旨在描述癌症患者/幸存者接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后的免疫接种后不良事件（AEFI）及其心理困扰情况。
开展了一项横断面研究，以评估马来西亚一家大学医院的癌症患者/幸存者接种SARS-CoV-2疫苗后的AEFI。在接种第一剂和第二剂2019冠状病毒病（COVID-19）疫苗前后，使用医院焦虑抑郁量表（HADS）测量心理困扰程度。
共收到217份完整回复。与接种疫苗前相比，接种第一剂和第二剂SARS-CoV-2疫苗后，医院焦虑抑郁量表焦虑分量表（HADS-A）和医院焦虑抑郁量表抑郁分量表（HADS-D）得分均显著降低。大多数参与者出现轻至中度的全身和局部AEFI，两剂疫苗最常见的是注射部位疼痛、疲劳和头痛。接种第一剂SARS-CoV-2疫苗后，观察到AEFI总分与HADS-A得分（r = 0.309，P < 0.001）和HADS-D得分（r = 0.214，P = 0.001）之间呈正相关。同样，接种第二剂SARS-CoV-2疫苗后，观察到AEFI总分与HADS-A得分（r = 0.305，P < 0.001）和HADS-D得分（r = 0.235，P < 0.001）之间呈正相关。
本研究中发现的轻至中度AEFI有助于解决癌症患者/幸存者对疫苗的犹豫态度。接种SARS-CoV-2疫苗对减轻癌症患者/幸存者的心理困扰有积极作用。AEFI的高严重程度与更高的焦虑和抑郁症状相关。
